Navigation Links
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Date:6/1/2009

First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL

ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ --

Intent to treat Analysis results per FDA agreed upon Statistical Analysis Plan

  • Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021
  • Significant Increase in Overall Response Rate 37.1% vs. 14.3%; p=0.003
  • Significant increase in percent of all patients whose response lasted greater than or equal to four months 25.7% vs. 8.6%; p=0.012
  • Significant Increase in Progression Free Survival 4.7 months vs. 2.6 months; p=0.007
  • Positive trend in Overall Survival even though data not fully mature with median 8.1 month vs. 6.9 month; p=0.544

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the 2009 American Society for Clinical Oncology ("ASCO") Annual Meeting for the first time since the top-line data were released, complete pivotal phase III results of CTI's EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial who presented the study at ASCO.

"Anthracycline-related drugs can be effective salvage agents in aggressive NHL, but our use of them is limited by the significant increase in risk of cardiac failure associated with high cumulative doses of these drugs," said Dr. Pettengell. "These results represent a breakthrough in that pixantrone could extend our ability to use a highly active anthracycline-like drug in such patients and deserves to be examined in anthracycline naive patien
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
2. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
3. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
7. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
8. New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
9. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
10. Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined
11. Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The Asia-Pacific hardware encryption display market ... with analysis and forecast of revenue. This market was ... reach $51,362.6 million by 2018, at a CAGR of ... TOC of the Asia-Pacific hardware encryption market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/18/2014)... According to a new market research report ... Global Trends & Forecasts up till 2017”, hydraulic fracturing ... This value is expected to increase from $40 billion ... CAGR during the same period. North America is expected ... terms of hydraulic horse power supplied by the year ...
(Date:10/17/2014)... through the looking-glass to Wonderland, mirrors in the real ... including a new class of mirror that works like ... Optical Society,s (OSA) new high-impact journal Optica ... a new type of mirror that forgoes a familiar ... using an unusual magnetic property of a non-metallic metamaterial. ...
(Date:10/17/2014)... (PRWEB) October 17, 2014 The ... Critical Radiant Boilers, Super Critical Boilers, Ultra Super ... (Combined Cycle Plants, Cogeneration Plants, Natural Gas Power ... Geography - Global Trends & Forecasts to 2019", ... with the analysis and forecast of the global ...
Breaking Biology Technology:The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 2Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 3Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 4Advanced Utility Boiler Market Worth $2,764.19 Billion by 2019 - New Report by MarketsandMarkets 5
... Update Conference Call Today at 8:30 a.m. EST, SOUTH ... RIGL ) today reported financial results for,the three and nine ... of 2008, Rigel reported a net loss of $37.7,million, or ... million, or,$0.61 per share, in the third quarter of 2007. ...
... SOUTH SAN FRANCISCO, Calif., Oct. 31 Rigel,Pharmaceuticals, Inc. ... senior management team will host a conference call with,simultaneous ... 2008 at,5:30 a.m. PST/8:30 a.m. EST., Conference Call ... please dial 800-265-0241 (domestic) or,617-847-8704 (international) 10 minutes prior ...
... SUNNYVALE, Calif., Oct. 31 Pathwork Diagnostics, ... City of Hope,Hospital presented today the results ... (IHC) to determine the origin of metastatic ... Molecular Markers in Cancer,in Hollywood, Fla. In ...
Cached Biology Technology:Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 2Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 3Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 4Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 5Rigel Announces Third Quarter 2008 Financial Results and Clinical Update 6Rigel to Host Update Conference Call 2Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests 2Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests 3
(Date:10/17/2014)... This news release is available in German . ... for only a very few drugs. When treating overdoses, doctors ... Treatment is especially difficult if there is a combination of ... is playing and accidentally swallows his grandmother,s pills? ETH professor ... Zurich wanted to find an answer to this question. "The ...
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... on how the bowel lining develops and, in the ... starts. , The researchers produced evidence that stem cells ... are a feature of the bowel lining, and believe ... a controversial finding as scientists are still divided on ... Dr Chin Wee Tan and Professor Tony Burgess from ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... -- Researchers have identified some of the underlying physics that ... stall in midflight -- unlike conventional fixed wing aircraft, where ... The analysis, in which the researchers studied the flow ... insects fly and informs the design of small flying robots ...
... 2013 A bicoastal group of scientists at Sanford-Burnham ... grant from the U.S. Department of the Air Force ... chemicals. The goal of the project is to provide ... a rapid, cost-effective manner. "The current approach to ...
... leave a bitter taste in one,s mouth" has a ... bitter substances, which, though found in healthful foods like ... ability to sense bitterness likely played an important role ... of Pennsylvania scientists provides new evidence underlining the significance ...
Cached Biology News:Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens 2Penn team elucidates evolution of bitter taste sensitivity 2Penn team elucidates evolution of bitter taste sensitivity 3Penn team elucidates evolution of bitter taste sensitivity 4
... Apoptosis is an evolutionarily conserved form of ... process. The central component of this ... called caspases. These enzymes participate in ... in response to pro-apoptotic signals and result ...
... Serum-free adapted Sf9 derivative for ... TriEx Sf9 Cells are derived from a ... growth in Novagen serum-free TriEx Insect Cell ... growth and protein yields by either baculovirus ...
... against a partial recombinant MAK. ... a.a) partial recombinant protein with GST tag. ... Accession: BC039825 Protein ... 154235, GeneID: 4117 ...
Mouse polyclonal antibody raised against a partial recombinant DDEF2. NCBI Entrez Gene ID = 8853...
Biology Products: